📰 Clinical Development Program News
Page 3 - Clinical Development Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Development Program. Real-time updates on events, politics, business and more.
December 11, 2023
/PRNewswire/ -- Detailed results from SURMOUNT-4, which showed Zepbound™ (tirzepatide) injection achieved superior mean percent change in body weight compared...
December 11, 2023
People who were randomized to placebo following the lead-in period experienced mean weight regain of 14.8% at 88 weeks, indicating Zepbound led to sustained weight loss compared to placebo Full results from the SURMOUNT-4 study were published in The Journal of the American Medical Association INDIANAPOLIS, Dec. 11, 2023 /PRNewswire/ — Detailed results from SURMOUNT-4, […]
October 23, 2023
Daiichi Sankyo and AstraZeneca’s ENHERTU showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population Results reaffirm...
October 20, 2023
First readout of two-year data from long-term extension study INDIANAPOLIS, Oct. 20, 2023 /PRNewswire/ -- Patients with moderate-to-severe atopic dermatitis who continued treatment with...
October 16, 2023
/PRNewswire/ -- Detailed results from Eli Lilly and Companys (NYSE: LLY) phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or...
October 13, 2023
These primary data of the ADvantage study were presented today at EADV Congress A total of 18 lebrikizumab abstracts were disclosed at EADV, including new data on the depth of response at Week 52...
October 13, 2023
Almirall's lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis (AD) in patients inadequately controlled with or ineligible for cyclosporine1 •      These primary data of the ADvantage study were presented today at EADV Congress •   &...
October 10, 2023
– Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous trials –– If approved by the FDA, RVO would be Vabysmo’s third indication in addition to wet age-related macular degeneration (AMD) and diabetic macular edema (DME) –– Vabysmo is the first and only treat...
October 4, 2023
This installment in our Unprevented series examines the growing impact of chronic kidney disease on public health and what those in the field are doing to mitigate this growing crisis.